FATE – Fate Therapeutics, Inc.
Fate Therapeutics, Inc.FATE
$1.04Name : Fate Therapeutics, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $119,218,312.00
EPSttm : -1.49
Fate Therapeutics, Inc.
$1.04
5.45%$0.06Float Short %
8.88
Margin Of Safety %
Put/Call OI Ratio
0.07
EPS Next Q Diff
0.01
EPS Last/This Y
0.4
EPS This/Next Y
0.09
Price
1.03
Target Price
5.4
Analyst Recom
2.3
Performance Q
17.97
Relative Volume
1.8
Beta
2.2
Ticker: FATE
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-06-02 | FATE | 1.29 | 0.07 | 0.00 | 5506 |
| 2025-06-03 | FATE | 1.36 | 0.07 | 0.00 | 5774 |
| 2025-06-04 | FATE | 1.425 | 0.07 | 0.00 | 5787 |
| 2025-06-05 | FATE | 1.34 | 0.07 | 0.00 | 5876 |
| 2025-06-06 | FATE | 1.6 | 0.07 | 0.00 | 5897 |
| 2025-06-09 | FATE | 1.52 | 0.04 | 0.08 | 11028 |
| 2025-06-10 | FATE | 1.67 | 0.04 | 0.03 | 11088 |
| 2025-06-11 | FATE | 1.55 | 0.04 | 0.01 | 12098 |
| 2025-06-12 | FATE | 1.39 | 0.04 | 0.00 | 11896 |
| 2025-06-13 | FATE | 1.27 | 0.04 | 0.01 | 12152 |
| 2025-06-16 | FATE | 1.23 | 0.04 | 0.02 | 12268 |
| 2025-06-17 | FATE | 1.195 | 0.04 | 0.04 | 12754 |
| 2025-06-18 | FATE | 1.2 | 0.04 | 1.40 | 12777 |
| 2025-06-20 | FATE | 1.18 | 0.05 | 0.00 | 13075 |
| 2025-06-23 | FATE | 1.145 | 0.07 | 0.00 | 5745 |
| 2025-06-24 | FATE | 1.17 | 0.07 | 0.00 | 5798 |
| 2025-06-25 | FATE | 1.16 | 0.07 | 0.00 | 5847 |
| 2025-06-26 | FATE | 1.09 | 0.07 | 0.00 | 5855 |
| 2025-06-27 | FATE | 1.03 | 0.07 | 0.33 | 5957 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-06-02 | FATE | 1.29 | -3.2 | - | -1.26 |
| 2025-06-03 | FATE | 1.36 | -3.2 | - | -1.26 |
| 2025-06-04 | FATE | 1.43 | -3.2 | - | -1.26 |
| 2025-06-05 | FATE | 1.34 | -3.2 | - | -1.26 |
| 2025-06-06 | FATE | 1.60 | -3.2 | - | -1.25 |
| 2025-06-09 | FATE | 1.52 | -3.3 | - | -1.25 |
| 2025-06-10 | FATE | 1.67 | -3.3 | - | -1.25 |
| 2025-06-11 | FATE | 1.55 | -3.3 | - | -1.25 |
| 2025-06-12 | FATE | 1.40 | -3.3 | - | -1.25 |
| 2025-06-13 | FATE | 1.27 | -3.3 | - | -1.24 |
| 2025-06-16 | FATE | 1.23 | -1.4 | - | -1.24 |
| 2025-06-17 | FATE | 1.19 | -1.4 | - | -1.24 |
| 2025-06-18 | FATE | 1.21 | -1.4 | - | -1.24 |
| 2025-06-20 | FATE | 1.19 | -1.4 | - | -1.24 |
| 2025-06-23 | FATE | 1.14 | -1.4 | - | -1.24 |
| 2025-06-24 | FATE | 1.17 | -1.4 | - | -1.24 |
| 2025-06-25 | FATE | 1.16 | -1.4 | - | -1.24 |
| 2025-06-26 | FATE | 1.09 | -1.4 | - | -1.24 |
| 2025-06-27 | FATE | 1.03 | -1.4 | - | -1.24 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-06-02 | FATE | 0.48 | -6.16 | 12.02 |
| 2025-06-03 | FATE | 0.48 | -6.16 | 12.02 |
| 2025-06-04 | FATE | 0.48 | -6.16 | 12.02 |
| 2025-06-05 | FATE | 0.48 | -6.16 | 12.02 |
| 2025-06-06 | FATE | 0.48 | -6.16 | 12.02 |
| 2025-06-09 | FATE | 0.48 | -6.15 | 12.02 |
| 2025-06-10 | FATE | 0.48 | -6.15 | 12.02 |
| 2025-06-11 | FATE | 0.48 | -6.15 | 10.31 |
| 2025-06-12 | FATE | 0.48 | -6.15 | 10.31 |
| 2025-06-13 | FATE | 0.48 | -6.15 | 10.31 |
| 2025-06-16 | FATE | 0.48 | -6.16 | 10.31 |
| 2025-06-18 | FATE | 0.48 | -6.16 | 10.31 |
| 2025-06-20 | FATE | 0.48 | -6.16 | 10.31 |
| 2025-06-23 | FATE | 0.48 | -6.16 | 10.31 |
| 2025-06-24 | FATE | 0.48 | -6.16 | 10.31 |
| 2025-06-25 | FATE | 0.48 | -6.16 | 10.31 |
| 2025-06-26 | FATE | 0.48 | -6.16 | 8.88 |
| 2025-06-27 | FATE | -0.27 | -6.16 | 8.88 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.32
Avg. EPS Est. Current Quarter
-0.33
Avg. EPS Est. Next Quarter
-0.31
Insider Transactions
-0.27
Institutional Transactions
-6.16
Beta
2.2
Average Sales Estimate Current Quarter
1
Average Sales Estimate Next Quarter
1
Fair Value
Quality Score
16
Growth Score
34
Sentiment Score
14
Actual DrawDown %
99.2
Max Drawdown 5-Year %
-99.4
Target Price
5.4
P/E
Forward P/E
PEG
P/S
8.94
P/B
0.41
P/Free Cash Flow
EPS
-1.49
Average EPS Est. Cur. Y
-1.24
EPS Next Y. (Est.)
-1.15
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-1318.93
Relative Volume
1.8
Return on Equity vs Sector %
-84.9
Return on Equity vs Industry %
-67
EPS 1 7Days Diff
EPS 1 30Days Diff
0.22
EBIT Estimation
Fate Therapeutics, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 181
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma; FT836 whiuch is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, and FT825 to treat solid tumors.It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
stock quote shares FATE – Fate Therapeutics, Inc. Stock Price stock today
news today FATE – Fate Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch FATE – Fate Therapeutics, Inc. yahoo finance google finance
stock history FATE – Fate Therapeutics, Inc. invest stock market
stock prices FATE premarket after hours
ticker FATE fair value insiders trading